Commentary Aripiprazole The Second Wave of the Second-generation AntipsychoticsKAHN, DAVID A., MDJournal of Psychiatric Practice®: March 2019 - Volume 25 - Issue 2 - p 146–147 doi: 10.1097/PRA.0000000000000373 CLINICAL CASE DISCUSSIONS Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Three cases are presented describing unique clinical responses to aripiprazole in comparison with other second-generation antipsychotics taken by each patient. One case involved an adverse reaction of problem gambling behavior, the second an enhanced antipsychotic response in delusional disorder, and the third a reversal of weight gain that occurred while the patient continued taking olanzapine. Aripiprazole was the first of a subgroup of atypical antipsychotics that are mixed agonists and antagonists of dopamine, likely contributing to unusual responses in some patients. KAHN: Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY The author declares no conflicts of interest. Please send correspondence to: David A. Kahn, MD, Department of Psychiatry, Columbia University College of Physicians and Surgeons, 601 West 168th Street, Unit 31, New York, NY 10032 (e-mail: firstname.lastname@example.org). Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.